Skip to main content

Methylphenidate News (Page 2)

FDA Medwatch Alert: Daytrana Patch (methylphenidate transdermal system): Drug Safety Communication - Permanent Skin Color Changes

ISSUE: FDA is warning that permanent loss of skin color may occur with use of the Daytrana patch (methylphenidate transdermal system) for Attention Deficit Hyperactivity Disorder (ADHD). FDA added a...

FDA Medwatch Alert: Methylphenidate ADHD Medications: Drug Safety Communication - Risk of Long-lasting Erections

ISSUE: FDA is warning that methylphenidate products (including Concerta, Daytrana, Focalin/Focalin XR, Metadate CD/Metadate ER, Methylin/Methylin ER, Quillivant XR, Ritalin/Ritalin LA/Ritalin SR),...

NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR for Once-Daily Treatment of ADHD

CUPERTINO, Calif., Oct. 1, 2012 /PRNewswire/ – NextWave Pharmaceuticals, an emerging specialty pharmaceutical company, announced FDA approval of Quillivant XR (methylphenidate hydrochloride) for...

FDA Approves Daytrana (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents

DUBLIN and PHILADELPHIA, July 6 /PRNewswire-FirstCall/ – Shire plc , the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Attention-Deficit Hyperactivity Disorder (ADHD), Narcolepsy, Depression, Fatigue, Weight Loss (Obesity / Overweight)

Related drug support groups

Concerta, Ritalin

Methylphenidate patient information at Drugs.com